BioMarin Pharmaceuticals
BMRN
392 hedge funds and large institutions have $12.4B invested in BioMarin Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 162 increasing their positions, 121 reducing their positions, and 38 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 121
18% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 38
17% more call options, than puts
Call options by funds: $102M | Put options by funds: $87.3M
0% more funds holding
Funds holding: 391 → 392 (+1)
0% more funds holding in top 10
Funds holding in top 10: 13 → 13 (0)
7% less capital invested
Capital invested by funds: $13.4B → $12.4B (-$986M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$78.5M |
| 2 |
HM
HealthCor Management
New York
|
+$63.8M |
| 3 |
IG
ING Group
Amsterdam,
Netherlands
|
+$62.7M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$59.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$48.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$229M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$203M |
| 3 |
JP Morgan Chase
New York
|
-$94.4M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$84.5M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$54.7M |
BMRN Hedge Fund Activity: Q2 2016 in Review
392 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2016, worth a combined $12.4B — down 7.3% from $13.4B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BMRN positions and 38 closed out — a net gain of 7 holders — while 162 added to existing stakes and 121 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $78.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $229M.
- 392 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2016, up from 391 in Q1 2016.
- Funds reported $12.4B of BioMarin Pharmaceuticals stock for Q2 2016, down 7.3% quarter-over-quarter.
- 45 funds opened new BioMarin Pharmaceuticals positions in Q2 2016 and 38 closed out, a net change of +7 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2016 was Alyeska Investment Group, an estimated $78.5M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2016 was T. Rowe Price Associates, an estimated $229M sold.
Based on aggregated 13F filings for Q2 2016.